Caricamento...
Myasthenia Gravis as an Immune-Mediated Side Effect of Checkpoint Inhibitors
This is a case report of new-onset myasthenia gravis (MG) as an immune-mediated adverse event (irAE) related to the use of pembrolizumab in a patient with undifferentiated adenocarcinoma of the pancreato-biliary tract. Up to this moment, only 52 cases of new-onset MG have been related to immune chec...
Salvato in:
| Pubblicato in: | Cureus |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Cureus
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8275066/ https://ncbi.nlm.nih.gov/pubmed/34277306 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.16316 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|